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 Figure 1: Areas with distinguishable respiratory motion (white) on the 
patient surface (a). After calibration, motion derived from the body 
surface highly correlates with the Amsterdam Shroud (b) 
 
 PROFFERED PAPERS: CLINICAL 1: PROSTATE CANCER  
  
OC-0048   
Long term results of the Dutch trial for localized prostate cancer: 
Impact on biochemical, clinical and local control 
J. Lebesque1, W. Heemsbergen1, A. Slot2, M. Dielwart3, W. van 
Putten4, A. Al-Mamgani5 
1The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, 
Radiation Oncology, Amsterdam, The Netherlands  
2Radiotherapeutic Institute Friesland, Radiation Oncology, 
Leeuwarden, The Netherlands  
3Zeeuws Radiotherapeutic Institute, Radiation Oncology, Vlissingen, 
The Netherlands  
4Erasmus Medical Centre-Daniel den Hoed Cancer Center, Statistical 
Department, Rotterdam, The Netherlands  
5Erasmus Medical Centre-Daniel den Hoed Cancer Center, Radiation 
Oncology, Rotterdam, The Netherlands  
 
Purpose/Objective: We studied the effect of a higher dose on tumor 
control for localized prostate cancer in a randomized trial with a 
median follow-up of 110 months. 
Materials and Methods: Patients with T1b-T4 prostate cancer were 
included in the period 1997-2003 (n=664) and randomized between 78 
Gy (n=333) and 68 Gy (n=331). Primary endpoint was biochemical 
and/or clinical failure (BCF) according the guidelines of the American 
Society for Therapeutic Radiology and Oncology (ASTRO) (3 
consecutive rises). Secondary endpoints were BCF using the Phoenix 
guidelines (nadir plus 2 µg/L), clinical failure (CF), local failure (LF), 
prostate cancer related death (PCRD), and overall survival (OS). 
Explorative subgroup analyses were performed. 
Results: Estimated freedom from BCF at 10 years according ASTRO 
was 45.9 % and 38.4 % for 78 Gy and 68 Gy, respectively (Log Rank, 
p=0.025). Freedom from BCF according Phoenix definition (Table) was 
superior in the 78 Gy arm as well (p=0.046). CF and OS were similar in 
both arms (Table). LF as a first event was significantly less observed in 
the 78 Gy arm (14 versus 27 events, p=0.036, Figure). For progression 
outside the prostate, i.e. documented regional or distant failure, we 
found more first events in the 78 Gy arm, which was not significant 
(59 versus 43 events, p=0.14). At the current update, 205 patients 
were deceased (104 in the 78 Gy arm), including 88 patients with 
PCRD (44 cases in both arms). Subgroup analysis for BCF showed a 
greater benefit for patients with PSA ≥ 10 ug/L compared to <10 ug/L 
(p<0.01 for heterogeneity). Within the subgroup PSA ≥ 10 ug/L, 
estimated freedom from BCF at 10 years (ASTRO) was 41.7 % for the 
78 Gy arm and 30.0 % for the 68 Gy arm (p=0.008). For the subgroup 
PSA < 10 ug/L, these numbers were 54.4 % and 52.6 %, respectively 
(p=0.9). 
 
 
Figure. Kaplan Meier for local failure as a first event (p=0.036) 
 
  
Conclusions: For the first time, a significant difference in LF is 
demonstrated in a randomized trial. However, despite significant 
differences in BCF and LF, no significant differences in CF and OS 
were observed after a median follow-up of 110 months. More follow-
up is needed to identify possible effects for these endpoints. Probably 
only subgroups of the trial population truly benefit from a higher local 
dose in terms of prolonged OS.  
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Purpose/Objective: Bone metastases from renal cell carcinoma (RCC) 
are common and often less responsive to palliative radiotherapy (RT) 
than metastases from other tumors. Sorafenib is a multi-targeted 
tyrosine-kinase inhibitor that improves progression-free survival in 
metastatic RCC. There is pre-clinical evidence to indicate that 
sorafenib also improves the effectiveness of RT. The purpose of this 
study was to examine the efficacy and toxicity of sorafenib in patients 
with RCC receiving palliative RT for painful bone metastases. 
Materials and Methods: Twelve patients with RCC and bone 
metastases were accrued to a phase I/II prospective study of RT and 
sorafenib. An index lesion was identified in each patient and treated 
to a dose of 30 Gy in 10 daily fractions. Sorafenib 200 mg or 400 mg 
per day was administered beginning one week before RT until at least 
nine weeks after RT. Patients who responded to sorafenib were 
eligible to continue beyond 12 weeks. Pain scores were evaluated 
using the Brief Pain Inventory (BPI). 18F-FDG PET imaging was 
performed at baseline (prior to any treatment) and four weeks after 
treatment to assess metabolic response. Standardized uptake values 
